Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) for Soft Tissue Sarcoma
Phase 1/2 Recruiting
74 enrolled
Retifanlimab (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue Sarcoma
Phase 1/2 Recruiting
98 enrolled
Gemcitabine and Docetaxel With Radiation in Adults With Soft Tissue Sarcoma of the Extremities
Phase 1 Terminated
9 enrolled
Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed Cancers
Phase 1 Terminated
272 enrolled
BIO-11006 for Osteosarcoma and Ewing's Sarcoma Lung Metastases
Phase 2 Withdrawn
GALLANT: Metronomic Gemcitabine, Doxorubicin, Docetaxel and Nivolumab for Advanced Sarcoma
Phase 2 Recruiting
260 enrolled
Phase 3 Study to Treat Patients With Soft Tissue Sarcomas
Phase 3 Completed
433 enrolled 10 charts
CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Synovial Sarcoma
Phase 1/2 Terminated
23 enrolled 15 charts
A Two-part Phase IIb Trial of Vigil (Bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Immunotherapy) in Ewing's Sarcoma
Phase 2 Completed
22 enrolled 13 charts
GemTax
Phase 1/2 Completed
37 enrolled 17 charts
Phase 2 Study of 9-ING-41 With Chemotherapy in Sarcoma
Phase 2 Withdrawn
A Phase 2 Study of 9-ING-41Combined With Chemotherapy in Adolescents and Adults With Advanced Sarcomas
Phase 2 Withdrawn
SOURCE
Phase 2 Completed
209 enrolled 18 charts
Bevacizumab, Chemotherapy and Valproic Acid in Advanced Sarcomas
Phase 1 Completed
47 enrolled
Study of Pembrolizumab Plus Chemotherapy in Patients With Advanced Cancer (PembroPlus)
Phase 1/2 Terminated
81 enrolled
Gemcitabine and Docetaxel in Combination With Pazopanib (Gem/Doce/Pzb) for the Neoadjuvant Treatment of Soft Tissue Sarcoma (STS)
Phase 1/2 Terminated
5 enrolled 6 charts
Docetaxel in Treating Patients With Refractory or Recurrent Advanced Gynecologic Cancer
Phase 1 Completed
18 enrolled
Gemcitabine With or Without Docetaxel as Second-Line Therapy in Treating Patients With Metastatic or Relapsed, Unresectable Uterine or Soft Tissue Leiomyosarcoma
Phase 2 Completed
90 enrolled
Docetaxel, Gemcitabine and Pazopanib as Treatment for Soft Tissue Sarcoma
Phase 1/2 Completed
6 enrolled
Gemcitabine and Docetaxel With Bevacizumab in Selected Sarcoma Subtypes
Phase 2 Completed
47 enrolled 7 charts
Evaluation of Side Effects and Relative Activity of Two Chemotherapy Regimens in the Treatment Soft Tissue Sarcoma
Phase 2 Completed
84 enrolled 7 charts
Phase IB Study of Gemcitabine, Docetaxel and Bevacizumab in Patients With Soft Tissue Sarcoma
Phase 1 Completed
38 enrolled
Trial of Docetaxel and Irinotecan (DI) for Recurrent or Refractory Bone and Soft Tissue Sarcomas.
Phase 2 Unknown
35 enrolled
Docetaxel, Gemcitabine, and Filgrastim (G-CSF) or Pegfilgrastim in Treating Patients With Advanced, Persistent, or Recurrent Uterine Leiomyosarcoma
Phase 2 Completed
STS
Phase 2 Completed
58 enrolled
Combination Chemotherapy Plus Filgrastim in Treating Patients With Advanced Solid Tumors
Phase 1 Completed
35 enrolled
Endostar + GT in Pulmonary Metastases of Soft Tissue Sarcoma
Phase 2 Unknown
30 enrolled
Gemcitabine, Docetaxel, and Filgrastim in Treating Patients With Recurrent or Persistent Leiomyosarcoma or Soft Tissue Sarcoma
Phase 2 Completed
82 enrolled
Docetaxel in Treating Children With Recurrent Solid Tumors
Phase 2 Completed
20 enrolled
Interaction of Docetaxel and Lonafarnib in Patients With Advanced Cancer
Phase 1 Terminated
38 enrolled
Gemcitabine and Docetaxel in Treating Patients With Recurrent Osteosarcoma (Closed to Accrual as of 12/21/06) or Ewing's Sarcoma or Unresectable or Locally Recurrent Chondrosarcoma
Phase 2 Completed
54 enrolled 8 charts
Thalidomide and Docetaxel in Treating Patients With Advanced Cancer
Phase 1 Completed
26 enrolled
Weekly Docetaxel and Fixed-Dose Rate Gemcitabine Combination Chemotherapy
Phase 2 Unknown
30 enrolled
Comparison of Gemcitabine v. Gemcitabine Plus Docetaxel in Unresectable Soft Tissue Sarcoma
Phase 3 Completed
120 enrolled